Chris Leben fails UFC Drug Test

012814-UFC-Chris-Leben-TV-Pi.vresize.1200.675.high.33Mixed martial arts, a sport widely practiced and promoted in USA, has churned some of the best fighters along time. The largest in the world of its kind, one name that truly stands as an epitome of world-class fighting talent is Chris Leben.
Having known to deliver five back-to-back victories in his inaugural series, this middleweight champion also fought for the now defunct WEC. What is also known of ‘The Crippler’ is him having failing the UFC drug test and being fined and suspended for one year. He was believed to be taking SARMS tested positive for prescription painkillers oxycodone,  and oxymorphone after his defeat at UFC 138. Previously too he had tested positive for Stanozolol, post his bout against Michael Bisping at UFC 89, for which he confronted a suspension of nine months.
He apologized to the organization, his family and friends for the embarrassment caused and asserted to make some ‘real changes’ in the coming year. In retrospect, UFC still regards Chris Leben as one of the best fighters it has produced.
In the professional circuit, the drug Stanozolol is widely used as a performance-enhancer due to its anabolic properties. It is predominantly sold under the label, ‘Winstrol’ and is a dihydrotestosterone derivative.

Stanozolol finds maximum usage among bodybuilders in their ‘cutting’ cycles, while retaining the lean body mass. It is said to accentuate bone density and red blood cell production and is not capable of converting into estrogen. However, its anabolic properties are still considered to be milder with it often being termed as a ‘reliable builder’. This indeed makes it a favorable steroid among both professional and non-professional body builders.
After enjoying success in the amateur circuit, Chris Leben holds to his credit the honor of not only winning his first five fights but also securing the Gladiator Challenge, Sportfight and WEC middleweight titles. He is presently competing in the Bellator MMA.

Updated: March 15, 2018 — 2:58 pm

Leave a Reply

Your email address will not be published. Required fields are marked * © 2016